Clinical Trials Logo

Clinical Trial Summary

PKU UP is a prospective, single-arm, open-label, 26-week acceptability study to evaluate PKU UP for the dietary management of participants with phenylketonuria (PKU). Up to 15 participants aged 1 - 10 years old will be recruited and it is anticipated the study will open in at least three sites in the United Kingdom (UK) to recruit the target number of participants in the required timeframe.


Clinical Trial Description

PKU is a rare inborn error of metabolism with a prevalence of 1 in 10,000 in the UK population. The mainstay of treatment for most individuals is dietary therapy with a strict protein-restricted diet. We propose to recruit children with a diagnosis of PKU aged 1-10 years. The study product, PKU UP, is a food for special medical purposes (FSMP), as defined by the Delegated Act EU 2016/128, used for the dietary management of Phenylketonuria (PKU). The study will be investigating the acceptability of PKU UP, as defined by the Advisory Committee on Borderline Substances (ACBS). This includes the following: - participant adherence to recommended intakes - gastrointestinal symptoms - evaluations of palatability. Each participant will be on the study for 26 weeks. This includes evaluation part 1 and evaluation part 2: - Part 1 consists of a 12 week period where participants introduce the study product into their diet. Gastrointestinal tolerance, metabolic control, compliance, product acceptability and dietary quality will be evaluated. - Part 2 consists of a 14 week period where participants continue to take the study product for a longer assessment of growth and nutritional status. Data collection will be performed using paper and/or electronic Case Report Forms completed by the investigators at the baseline, evaluation periods and end of study visits. There will also be three questionnaires completed by the parents/guardians over the course of the study, in relation to protein substitute intake, gastrointestinal tolerance, and product acceptability. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05995717
Study type Interventional
Source Vitaflo International, Ltd
Contact Clinical Trials
Phone 0151 709 9020
Email ClinicalTrialsTeam@Vitaflo.co.uk
Status Recruiting
Phase N/A
Start date January 11, 2024
Completion date September 11, 2025

See also
  Status Clinical Trial Phase
Completed NCT02212288 - Antioxidant Signature in Adult Patients With Phenylketonuria Phase 4
Completed NCT05062226 - GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYR N/A
Terminated NCT01904708 - Moderate Intensity Exercise and Phenylketonuria N/A
Completed NCT01619722 - Study of a National Cohort of Adult Patients With Phenylketonuria
Completed NCT03913156 - Feeding Patterns and Practices in Young Children With PKU During the First Two Years of Life N/A
Recruiting NCT05051657 - Evaluation of the Express Plus Range N/A
Completed NCT04309331 - Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute N/A
Completed NCT04679467 - Evaluation of PKU Sphere in Italy N/A
Completed NCT04318509 - Market Research - Acceptability Study for a New PKU Protein Substitute N/A
Withdrawn NCT01412437 - Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria N/A
Terminated NCT04768348 - Natural History Clinical Study in Adult PKU